AXQ Capital LP Takes $2.97 Million Position in Zoetis Inc. $ZTS

Key Points

• AXQ Capital LP initiated a $2.97 million position in Zoetis during the second quarter by purchasing 41,355 shares. Institutional investors collectively own 92.8% of the company.
• Zoetis reported quarterly EPS of $1.87, exceeding estimates of $1.85, while revenue declined 0.2% year over year to $2.47 billion. The company set fiscal 2026 EPS guidance at $6.15–$6.25.
• Shares opened at $76.34, near their 52-week low of $71.00, and analysts have a consensus “Hold” rating with an average price target of $107.43.

AXQ Capital LP bought a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 41,355 shares of the company's stock, valued at approximately $2,972,000.

A number of other large investors have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Zoetis in the second quarter valued at approximately $25,000. Dunhill Financial LLC grew its position in Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company's stock valued at $25,000 after purchasing an additional 296 shares in the last quarter. Prosperity Bancshares Inc acquired a new stake in Zoetis in the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis in the 1st quarter valued at $28,000. Finally, Root Financial Partners LLC lifted its position in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock worth $30,000 after buying an additional 103 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

NYSE:ZTS opened at $76.34 on Friday. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $155.15. The firm has a market cap of $31.55 billion, a price-to-earnings ratio of 12.58, a P/E/G ratio of 1.78 and a beta of 0.73. The firm's 50-day simple moving average is $75.53 and its 200 day simple moving average is $93.97. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the business posted $1.76 EPS. The business's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Morgan Stanley set a $85.00 price objective on Zoetis in a research note on Friday, August 7th. Citigroup lowered their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 1st. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. Finally, Argus reiterated a "hold" rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $107.43.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source